This page is solely managed by the hospital for all communications.

Dr. Hulya Hamzaoglu

Crohn’s disease · Therapeutic endoscopy

Free Call - Call hospitals worldwide for free using the internet

Acibadem Fulya Hospital

Istanbul, Turkey








Medical staff

Contact Information

Dikilitas, Hakki Yeten Cd. No:23, 34349 Besiktas/Istanbul, Turkey


Dr. Hulya Hamzaoglu is a gastroenterologist at Acıbadem Fulya Hospital. She graduated from the Faculty of Medicine at Istanbul University Cerrahpasa in 1988. After graduation, she finished her residency in Internal medicine. In 1993 she went to Beth Israel Hospital, Harvard Medical School Boston-USA, Gastroenterology Division, where she trained for one year in her area of interest. After returning to Turkey, she took further training in Gastroenterology and became a gastroenterologist in 1996 from the Turkey High Specialization Training and Research Hospital. In 1997 she went to Germany for one year and did further training at Giessen University. In 2004 she again went to Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, U.S.A. to further training in the Inflammatory Bowel Clinic. Being a highly competent doctor, she joined the Acibadem Fulya Hospital in 2010 and since then has been working there as a professor of Gastroenterology. Dr. Hulya Hamzaoglu has a particular clinical interest in inflammatory bowel diseases and chronic diseases of the intestine. She has a specific interest in the treatment of Crohn's Disease and Colitis. She has also taken special training in Therapeutic Endoscopy. Dr. Hulya Hamzaoglu is a member of the Turkish Gastroenterology Society and the Turkish Liver Studies Association. She is the president of the Inflammatory Bowel Diseases Association. She has various publications to her name, including the "Safety of infliximab in Crohn's Disease: A large single¬ center experience" published in the Inflammatory Bowel Diseases journal on April 9, 2010. Some other articles include the Clinical outcome of Crohn's disease treated with Infliximab submitted in the Hepato-Gastroenterology journal in 2003.